ArticleFrontiers in pharmacology2026
CX-01 mitigates trauma-induced acute kidney injury and improves survival in a combat-relevant polytrauma rat model.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Previous studies have shown that polytrauma may initiate a systemic inflammatory response that drives acute kidney injury (AKI), multiple organ failure (MOF), and high mortality. However, beyond supportive care, pharmacological treatments for trauma-induced AKI are lacking, which represents a serious unmet clinical need. Previous work from our group identified the inflammatory mediator high mobility group box 1 (HMGB1) as a promising therapeutic target to mitigate MOF and AKI. We have shown that HMGB1 levels correlate with organ failure, such as AKI, acute respiratory distress syndrome (ARDS), and MOF. In this study, we investigated CX-01, a modified heparin and HMGB1 inhibitor, to determine if it can reduce AKI and improve survival in a rat polytrauma model. Male Sprague-Dawley (SD) rats underwent polytrauma consisting of soft tissue injury, fibula fracture and pressure-controlled hemorrhage (MAP 55 mmHg) for 2 hours followed by whole blood resuscitation to maintain MAP at 90 mmHg for 30 min. Animals were randomly assigned to either a vehicle control group (vehicle, n = 9), or a therapeutic treatment group which received CX-01 (25 mg/kg, n = 8) at specified intervals over a 72-h observation period. Vital signs, hemodynamics, blood chemistry, inflammation, and tissue damage were collected and analyzed. Treatment with CX-01 significantly increased survival over the 72-h study period (87.5% vs. 33.3%,
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.